GLP-1 Agonist Therapy Center

Melanie Sulistio, MD, Curtis Carothers, MD, Mandeep Mange, BS, Mike Lujan, BS, Rene Ofiveros, MD, and Robert Chilton, DO Cardiovascular disease is a leading cause of death in the United States and across the world, and better therapies are constantly being sought to improve patient outcomes. Recent studies have brought …

See more GLP-1 Agonist Resources. This week we wrap-up our four part series on GLP-1 Agonists. Topics covered this week include: "Treatment with Exenatide does not impair the counterregulatory glucagon response," "Incretin-related Anti-diabetes Drugs and effects on plasma glucagon," and "A new extra-islet target for GLP-1: The Heart"…. Link to …

This week, we present Part 3 of a series of 4 Homerun Slide collections covering GLP-1 Agonist therapy. This week’s slides present findings on the therapeutic effects of GLP-1, GLP-1 agonists and DPP-IV inhibitors (which increase circulating levels of endogenous active GLP-1 and GIP) in patients with T2DM…. Link to …

This week, we continue with Part 2 of our Homerun Slides series on GLP-1 Agonist Therapy…. Link to download (.ppt format): GLP-1 Effectiveness, Mechanisms of Action and Potential, Part 2 of 4 Other sets in this series: GLP-1 Effectiveness, Mechanisms of Action and Potential, Part 1 of 4 GLP-1 Effectiveness, Mechanisms …

With this special bonus edition of our highly successful GLP-1 special series, we provide you with an easy list so you can find all of our analyses in one place…. Just click on these links to access each analysis. GLP-1 Knowledge Survey Part I GLP-1 Knowledge Survey Part II GLP-1 …

Topics covered include the clinical effects of GLP-1 agonists and DPP-4 inhibitors stemming from incretin action, and the role of glucagon in glucose intolerance and effects of GLP-1 based drugs on plasma glucagon…. Link to download (.ppt format): GLP-1 Effectiveness, Mechanisms of Action and Potential, Part 1 of 4 Other sets …

Oxyntomodulin is a gut peptide released in response to a meal. It is synthesized within specialized enteroendocrine cells called L cells. Oxyntomodulin is released from the intestinal L cells 5-10 minutes after ingestion of food in amounts proportional to calorie intake and levels peak 30 minutes after meals. Oxyntomodulins are …

When making a choice amongst GLP-1 Agonists, the number of injections per day and when peak concentrations are reached are both important in selecting therapy. There was almost unanimous consensus that Exenatide is administered twice daily while Liraglutide is given only one time a day. It was interesting to note …

Glucagon-like peptide-1 mimetics improve certain cardiovascular risk factors, although it is unclear if the observed benefits are direct effects or indirect effects due to weight loss. Improvements in systolic blood pressure seen in exenatide and liraglutide trials are illustrated in Figure 3. The decreases in systolic blood pressure range from …

This week we examine more of your responses regarding GLP-1 therapy…. See more GLP-1 Agonist Resources. I was glad to see that almost everyone realized that when a GLP-1 agonist is added to a sulfonylurea that it is not the GLP-1 agonist that is responsible for any side effects. It’s …